Skip to main content

Table 1 Immunocompromised patients’ characteristics

From: Gastrointestinal bleeding in critically ill immunocompromised patients

Characteristics Patients
N = 141
Generalities
 Age, median [IQR] 60 [48–69]
 Male gender, n (%) 89 (63)
 BMI, median [IQR] 24 [21–29]
Immunosuppression factor
 Hematological malignancy, n (%) 93 (66)
 Auto-immune disease, n (%) 17 (12)
 Solid organ transplant, n (%) 17 (12)
 HIV, n (%) 24 (17)
 Corticosteroids, n (%) 72 (51)
 Chemotherapy, n (%) 61 (43)
 Other immunosuppressive drugs, n (%) 37 (26)
 Allograft, n (%) 9 (6)
Treatments at admission
 Anticoagulants, n (%) 36 (26)
 Antiplatelet agent, n (%) 21 (15)
 PPI before admission, n (%) 69 (49)
GIB characteristics
 Upper GIB, n (%) 103 (73)
 Delay ICU—GIB, median [IQR], days 0 [− 2.1 to 1.25]
 Melena, n (%) 90 (64)
 Hematochezia, n (%) 51 (36)
 Hematemesis, n (%) 42 (30)
Biology during GIB
 Thrombopenia < 50 G/L, n (%) 56 (40)
 Hemoglobin (nadir) (g/dl), median [IQR] 6,6 [2, 5–7]
 PT (%), median [IQR] 69 [57–77.5]
 ACT, median [IQR] 1.15 [1–1.5]
 Lactatemia (mmol/l), median [IQR] 2.1 [1.2–3.9]
 Fibrinogen (g/l), median[IQR] 3.095 [2.062–4.825]
Organ failure
 Shock, n (%) 64 (45)
 Vasopressive drugs, n (%) 55 (39)
 Renal replacement therapy, n (%) 44 (31)
 Mechanical ventilation, n (%) 110 (79)
 SOFA score during GIB, median [IQR] 6 [3–12]
Transfusion
 RBC units, median [IQR] 5 [3–10]
 Platelets units, median [IQR] 6 [0–19]
 FFP units, median [IQR] 0 [0–2]
 Fibrinogen concentrates, n (%) 7 (5)
 Tranexamic acid, n (%) 5 (4)
Etiologies
 Ulcers, any cause, n (%) 38 (27)
 Malignant lesion, n (%) 36 (26)
 Variceal bleeding, n (%) 15 (11)
 Infectious cause, n (%) 13 (9)
 Angiodysplasia, n (%) 8 (6)
 Noninfectious colitis, n (%) 8 (6)
 Diverticular hemorrhage, n (%) 4 (3)
 Graft versus host disease, n (%) 2 (1)
 Other, n (%) 17 (12)
Interventional care
 EGD, hemostatic procedure, n (%) 59 (42)
 Colonoscopy, n (%) 42 (30)
 CT angiography, n (%) 34 (24)
 Arterio-embolization, n (%) 10 (7)
 Hemostatic surgery, n (%) 10 (7)
 AIM65 score ≥ 2, n (%) 105 (74)
ICU stay, median [IQR], days 5 [2–11]
Relapses, n (%) 38 (27)
ICU mortality, n (%) 30 (21)
Mortality at day 30, n (%) 39 (28)
Mortality at day 90, n (%) 54 (38)
Mortality due to GIB, n (%) 18 (13)
  1. BMI body mass index, HIV human immunodeficiency virus, PPI proton pump inhibitor, ICU intensive care unit, GIB gastrointestinal bleeding, PT prothrombin time, ACT activated coagulation time, SOFA sequential organ failure assessment, RBC red blood cell, FFP fresh frozen plasma, GVH graft versus host, EGD esophagogastroduodenoscopy, CT computed tomography